Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 26,889 shares of the firm's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $27.80, for a total value of $747,514.20. Following the completion of the transaction, the chief executive officer owned 2,388,014 shares in the company, valued at approximately $66,386,789.20. This trade represents a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Viking Therapeutics Price Performance
Viking Therapeutics stock traded up $0.44 during trading hours on Friday, hitting $28.16. The company had a trading volume of 2,383,469 shares, compared to its average volume of 4,040,100. Viking Therapeutics, Inc. has a fifty-two week low of $18.92 and a fifty-two week high of $81.73. The firm has a market capitalization of $3.16 billion, a P/E ratio of -24.49 and a beta of 0.62. The firm's fifty day moving average is $27.42 and its 200-day moving average is $29.71.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same period in the prior year, the business earned ($0.26) earnings per share. Viking Therapeutics's revenue was up .0% on a year-over-year basis. Analysts anticipate that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Hedge Funds Weigh In On Viking Therapeutics
Hedge funds have recently added to or reduced their stakes in the company. Quarry LP grew its position in Viking Therapeutics by 1,621.4% in the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 1,135 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of Viking Therapeutics by 64.8% in the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 536 shares during the last quarter. FIL Ltd boosted its holdings in Viking Therapeutics by 116.8% in the fourth quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 648 shares in the last quarter. NBC Securities Inc. increased its position in Viking Therapeutics by 222,100.0% during the first quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock worth $53,000 after buying an additional 2,221 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in Viking Therapeutics by 170.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock valued at $55,000 after buying an additional 851 shares in the last quarter. Institutional investors and hedge funds own 76.03% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently weighed in on VKTX. Morgan Stanley lowered their price target on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. The Goldman Sachs Group began coverage on Viking Therapeutics in a research report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 target price on the stock. Truist Financial reissued a "buy" rating and issued a $75.00 price target (down previously from $95.00) on shares of Viking Therapeutics in a report on Monday, April 28th. HC Wainwright restated a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, June 25th. Finally, Cantor Fitzgerald raised Viking Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $87.15.
Get Our Latest Analysis on Viking Therapeutics
Viking Therapeutics Company Profile
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
